We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,677.00
Bid: 1,677.00
Ask: 1,677.50
Change: 7.00 (0.42%)
Spread: 0.50 (0.03%)
Open: 1,661.50
High: 1,678.50
Low: 1,658.50
Prev. Close: 1,670.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-We're unlikely to see a repeat of late 2018 rout

Wed, 30th Oct 2019 11:44

* European shares flat before Fed meeting
* Fiat Chrysler and PSA confirm tie-up talks, stocks rally
* Bank earnings in focus: DB, CS, StanChart, Santander
* Fed seen cutting rates, focus on policy outlook

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your
thoughts on market moves: rm://julien.ponthus.thomsonreuters.com@reuters.net

WE'RE UNLIKELY TO SEE A REPEAT OF LATE 2018 ROUT (1144 GMT)
So far we haven't seen any signs of a repeat of last year's fourth-quarter rout that
instilled fear that the bull market was coming to an end.
"They (investors) seem to be worried about a repeat of the painful de-risking seen in
November and December last year, but we believe it is unlikely to materialise," Barclays equity
strategists led by Emmanuel Cau say in a note.
The deeply unloved rally continues and Cau says hedge funds have reduced their equity shorts
but are not net long yet while exposure to bonds is still crowded.
"Investors' dislike of equities lowers the odds of another episode of painful year-end
derisking and suggests the bar for positive surprises is not high."
On rotation, Barclays says value rotation could get fresh legs to run if activity momentum
stabilises and central banks do not surprise on the dovish side anymore.
Here's a chart on high 2020 earnings expectations and market's de-risking in late 2018, when
2019 expectations came of rails:


(Thyagaraju Adinarayan)
*****


UK HOUSEBUILDERS ON ELECTION WATCH (0945 GMT)
So now we have an election date -- Dec. 12 -- and housebuilders are among the sectors that
could be affected.
Liberum has taken a look and how the industry fared in the run up to the past voting rounds
and crossing that with current indications from polls showing a Tory majority win, concludes
there might be an opportunity here for investors.
"If history is a guide we should expect the housing market to slow in the run-up to the
announced general election, but if the opinion polls and bookmakers are correct, the
housebuilders shares could outperform if a Conservative victory is the outcome," analyst at
Liberum say.
"It is difficult to see a clear picture in how housebuilders' shares perform immediately
before or after a general election, although we do note that the sector performed well during
the 2015 and 2017 elections won by the Conservatives," they add.


(Danilo Masoni)
*****



OPENING SNAPSHOT: PSA AND FIAT CHRYSLER STEALS THE SHOW (0828 GMT)
It's the main headline of the day so it's only fair in a way that PSA and Fiat
Chrysler get the spotlight this morning with their shares surging 8.7% and 7.5%
respectively.
The French carmaker is the top performer on its home turf and same goes for its Italian
would-be match in Milan. The brides are well in the race for the top spot on the STOXX 600
.
Although both stocks are on fire, they will struggle to catch up Germany's Fuchs Petrolub
which jumped about 12% on the back of better-than-expected earnings.
It's not only fun and joy in the sector though with Renault, PSA's arch rival,
falling 4% as its shareholders are probably getting a big blast of Fomo.
What could also curb the enthusiasm for the sector is Pirelli's 5.5 percent fall
after the tyre maker cut its guidance.
It seems to a good day for France Inc with L'Oreal up 6 percent as it defies the
perceived gloom of the Chinese market. The French benchmark is up 0.2%.
Plenty of action in the banking sector with Deutsche Bank posting the worst
performance of the DAX with a 4% fall after yet another quarterly loss.
Bayer on the other hand took the lead for German blue chips, rising 2.5% on solid
results.
Because the overall market has no clear directional trend yet, here's a look at the top
movers on the STOXX 600 instead:

(Julien Ponthus)
*****


ON THE RADAR: CORPORATE TOP NEWS OVERLOAD (0736 GMT)
Futures have opened sideways with no clear directional trend in Europe.
What's clear however is that there is such a huge flow of corporate news that it will be
difficult to be sure not to have missed anything before the open and the market, which tends to
be quite unforgiving these days, gives its verdict.
Before getting in the Q3 action, let's first flag out a major piece of news in the auto
industry with Fiat Chrysler confirming talks with French rival PSA for a
potential tie-up.
News of the tentative merger comes as Germany's Volkswagen lowered its full-year
outlook for vehicle deliveries, warning of slowing demand.
Lots to take in the banking industry too:
Deutsche Bank reports 832 million euro Q3 loss on restructuring
StanChart flags growth, interest rate headwinds after Q3 profit beat
Credit Suisse doubles Q3 net profit

Santander Q3 net profit falls 75% as UK charges offset Brazil strength

But there are heavyweights across all sectors making headlines this morning so in no
particular order, he's the rest of the top news: click here to get it on Eikon:
Airbus cuts delivery goal on Hamburg plant snags
Record Q3 output boosts Total's cash flow, low prices hit profit
Lower oil and gas prices weigh on OMV Q3 profit
Bayer says number of glyphosate plaintiffs jumps to 42,700

Clariant Q3 profit and sales fall as economic climate worsens
Angry Birds maker Rovio's Q3 profit halves year-on-year
EssilorLuxottica confirms 2019 targets after stronger Q3 sales
Britain's Next keeps full year guidance after Q3 sales rise
(Julien Ponthus)
*****


FED WATCHING, Q3 GALORE AND THE XMAS BREXIT ELECTION (0542 GMT)
Christmas will come early to the UK this year, precisely on December 12 in the form of a UK
general election.
It's far from certain however that the polls will deliver anything on Boris Johnson or
Jeremy Corbyn's wish list but less than 48 hours ahead of Halloween, investors aren't spooked by
the prospect of the process going all wrong.
The pound is roughly stable at 1.2870 and according to IG, financial spreadbetters expect
London's FTSE to open just 7 points lower, so nothing dramatic there indeed.
Frankfurt's DAX is also seen retreating slightly at the open by 25 points but Paris is
should be flat.
With Wall Street on and off record highs, the Fed's meeting today and the expected interest
rate cut will be key, especially after it emerged that Washington and Beijing may not complete
their interim trade agreement in time to sign in Chile next month.
Amid all that news let us not forget that we are in for one of the busiest day of the Q3
season with a flurry of results such as Bayer, GlaxoSmithKline, Suez
or Total.
Last but not least, there will also be a deluge of indicators from the euro zone which
should shed more light on whether there is light to be seen at the end of the macro gloom
tunnel.
(Julien Ponthus)
*****


(Reporting by Danilo Masoni, Joice Alves, Julien Ponthus and Thyagaraju Adinarayan)

More News
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.